Nilutamide NEW
| Price | $39 | $91 |
| Package | 100mg | 500mg |
| Supply Ability: | 10g |
| Update Time: | 2026-06-02 |
Product Details
| Product Name: Nilutamide | CAS No.: 63612-50-0 |
| Purity: 98.67% | Supply Ability: 10g |
| Release date: 2026/06/02 |
Product Introduction
Bioactivity
| Name | Nilutamide |
| Description | Nilutamide (RU23908), an antineoplastic hormonal agent, is mainly used in the treatment of prostate Y. Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors, but not for estrogen, progestogen, or glucocorticoid receptors. Therefore, Nilutamide can block the action of androgens of testicular and adrenal origin that stimulate the growth of malignant and normal prostatic tissue. Prostate Y is mainly androgen-dependent and can be treat with chemical castration or surgical. So far, antiandrogen monotherapy has not consistently been certified to be equivalent to castration. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+90% Saline : < 10 mg/mL (31.52 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 10 mg/mL (31.52 mM), Solution. DMSO : 250 mg/mL (788.1 mM), Sonication is recommended. |
| Keywords | T-47D | Schistosoma | RU-23908 | RU 23908 | prostate cancer | Parasite | Nilutamide | Nilandron | Inhibitor | inhibit | antischistosomal | anticancer | AndrogenReceptor | Androgen Receptor |
| Inhibitors Related | Flubendazole | Kojic acid | Gum arabic | Urethane | Hydroxychloroquine | Metronidazole | 2-Amino-2-methyl-1-propanol | Doxycycline | Enzalutamide | Fenpyroximate | Methylene Blue trihydrate | Coumaran |
| Related Compound Libraries | Anti-Parasitic Compound Library | Failed Clinical Trials Compound Library | Bioactive Compound Library | ReFRAME Related Library | Drug-induced Liver Injury (DILI) Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:179479-04-0
-
-
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $39.00 |
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-06-02 | |
| $39.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-06-02 | |
| $1.10 |
VIP6Y
|
Dideu Industries Group Limited
|
2025-11-18 | |
|
VIP4Y
|
Henan Aochuang Chemical Co.,Ltd.
|
2025-04-04 | ||
|
VIP7Y
|
Shaanxi Dideu Medichem Co. Ltd
|
2020-04-30 | ||
| $7.00 |
VIP8Y
|
Career Henan Chemical Co
|
2019-09-03 | |
| $39.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2025-06-09 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY